Clinical, Angiographic, and IVUS Results from the Pivotal U.S. Randomized SPIRIT III Trial of the XIENCE[™] V Everolimuseluting Coronary Stent System

> Gregg W. Stone, MD for the SPIRIT III Investigators

Background

The XIENCE[™] V DES elutes everolimus from a thin (7.8 um), robust, durable biocompatible fluoropolymer, incorporating thin cobalt chromium stent struts (0.0032") for enhanced flexibility and deliverability.

The 300 pt randomized SPIRIT II trial found that the XIENCETM V stent compared to the TAXUS stent reduced angiographic late loss at 6 months (0.11 \pm 0.27 mm vs. 0.36 \pm 0.39 mm, P<0.0001).

The SPIRIT III trial was thus designed as the U.S. pivotal approval study for the XIENCE[™] V stent.



Study Algorithm

1002 pts enrolled at 65 U.S sites

RVD \geq 2.5 mm - \leq 3.75 mm; Lesion length \leq 28 mm Max. 2 lesions each in a different epicardial vessel

> Pre-rand: ASA \geq 300 mg, clopidogrel \geq 300 mg load unless on chronic Rx

Randomized 2:1 XIENCE V:TAXUS

Stratified by diabetes and intent for 1 vs. 2 lesion treatment Pre-dilatation mandatory

Everolimus-eluting
XIENCE V

Paclitaxel-eluting TAXUS


Aspirin \geq 80 mg QD for 5 years; Clopidogrel 75mg QD for \geq 6 months Clinical f/u: 1, 6, 9 months and yearly for 1-5 years Angio f/u (N=564) @ 8 mos; IVUS f/u (N=240) @ 8 mos

SPIRIT III Endpoints


- Primary Endpoint: In-segment late loss (LL) at 8 months
 - Assume LL = 0.24 \pm 0.47 mm in both arms
 - Non-inferiority margin = 0.195 mm, one-sided α = 0.025
 - 564 total pts \Rightarrow 99% power (assuming 10% dropout)
 - Pre-specified sequential non-inferiority and superiority tests
 - In pts with 2 lesions, primary endpoint analysis based on a randomly assigned "analysis lesion"
- Major Secondary Endpoint: Ischemia-driven target vessel failure (TVF) at 9 months
 - Assume TVF rate = 9.4% in both arms
 - Non-inferiority margin = 5.5%, one-sided α = 0.05
 - 1,002 total pts \Rightarrow 89% power (assuming 1% dropout)
- Both 1° and major 2° endpoints must be met for success



Patient Flow - Clinical



Patient Flow - Angiographic



Baseline Demographics

	XIENCE V 669 pts	TAXUS 333 pts	P value
Age (in years)	63.2 ± 10.5	62.8 ± 10.2	0.54
Male (%)	70.1	65.7	0.17
Hypertension (%)	76.2	74.0	0.48
Hypercholesterolemia (%)	74.2	71.5	0.36
Diabetes mellitus (%)	29.6	27.9	0.60
Insulin requiring (%)	7.8	5.5	0.19
Current smoker (%)	23.4	22.5	0.81
Prior MI (%)	19.9	18.0	0.49
Unstable angina (%)	18.7	25.1	0.02



Baseline Angiography

	XIENCE V 767 lesions	TAXUS 382 lesions	P value
Lesion location			
LAD	41.3%	42.9%	0.61
LCX	27.6%	28.3%	0.83
RCA	31.0%	28.5%	0.41
LMCA	0.1%	0.3%	0.55
QCA			
RVD (mm)	$\textbf{2.77} \pm \textbf{0.45}$	$\textbf{2.76} \pm \textbf{0.46}$	0.87
MLD (mm)	$\textbf{0.82}\pm\textbf{0.41}$	$\textbf{0.83}\pm\textbf{0.40}$	0.79
% DS	70.0 ±13.3	69.4 ±13.6	0.54
Lsn length (mm)	$\textbf{14.7} \pm \textbf{5.6}$	14.7 ± 5.7	0.92

Spirit III

Procedural Results

	XIENCE V 669 pts 768 lesions	TAXUS 332 pts 382 lesions	P value
# lesions/pt*	1.2 ± 0.4	1.2 ± 0.4	1.0
2 lesion pts*	15.4%	15.4%	1.0
# stents/pt [†]	1.3 ± 0.6	1.3 ± 0.5	0.27
# stents/lesion [†]	1.2 ± 0.4	1.1 ± 0.3	0.07
Max. stent diameter/lesion (mm)	$\textbf{3.0} \pm \textbf{0.4}$	$\textbf{3.0} \pm \textbf{0.4}$	1.0
Max. stent diameter/RVD	1.1 ± 0.1	1.1 ± 0.1	0.56
Total stent length/lesion	22.8 ± 8.4	21.6 ± 7.8	0.02
Total stent length/lesion length	1.6 ± 0.5	1.5 ± 0.5	0.01
Maximum pressure (atm.)	14.8 ± 2.9	15.1 ± 2.6	<0.05

* All vessels had a single lesion except 5 pts in whom a single vessel had two lesions † Of 1,322 total stents implanted, 8 were non study stents




Post Procedure QCA

	XIENCE V	TAXUS	Р
	766 lesions	379 lesions	value
RVD (mm)	$\textbf{2.84} \pm \textbf{0.45}$	2.84 ± 0.46	0.74
Acute gain (mm)			
In-segment	1.54 \pm 0.51	$\textbf{1.53} \pm \textbf{0.50}$	0.62
In-stent	1.89 \pm 0.48	1.91 \pm 0.47	0.56
MLD (mm)			
In-segment	$\textbf{2.37} \pm \textbf{0.45}$	$\textbf{2.36} \pm \textbf{0.45}$	0.73
In-stent	$\textbf{2.71} \pm \textbf{0.43}$	$\textbf{2.74} \pm \textbf{0.41}$	0.38
% DS			
In-segment	13.5 ±7.6	$\textbf{14.4} \pm \textbf{7.1}$	0.06
In-stent	0.3 ± 8.9	-0.2 ± 9.9	0.37



Primary Endpoint: In-segment LL at 8 Months* (Analysis Lesion)



Late Loss at 8 Months*

	XIENCE V 301 patients	TAXUS 134 patients	P value
Analysis lesion	301 lesions	134 lesions	
In-segment	0.14 ± 0.41	0.28 ± 0.48	0.004
In-stent	0.16 ± 0.41	0.31 ± 0.55	0.006
All lesions	343 lesions	158 lesions	
In-segment	0.14 ± 0.39	$\textbf{0.26}\pm\textbf{0.46}$	0.003
In-stent	0.16 ± 0.41	0.30 ± 0.53	0.002
In-stent All lesions In-segment	0.16 ± 0.41 343 lesions 0.14 ± 0.39	0.31 ± 0.55 158 lesions 0.26 ± 0.46	0.006



*F/U window \pm 28 days.


QCA at 8 Months* (All Lesions)

XIENCE V 344 lesions	TAXUS 158 lesions	P value
$\textbf{2.77} \pm \textbf{0.43}$	2.78 ± 0.42	0.84
$\textbf{2.22} \pm \textbf{0.53}$	$\textbf{2.12} \pm \textbf{0.60}$	0.08
$\textbf{2.56} \pm \textbf{0.53}$	$\textbf{2.45} \pm \textbf{0.65}$	0.07
18.8 ± 14.4	22.8 ± 16.4	0.008
5.9 ± 16.4	10.3 ± 21.4	0.02
	344 lesions 2.77 \pm 0.43 2.22 \pm 0.53 2.56 \pm 0.53 18.8 \pm 14.4	344 lesions158 lesions 2.77 ± 0.43 2.78 ± 0.42 2.22 ± 0.53 2.12 ± 0.60 2.56 ± 0.53 2.45 ± 0.65 18.8 ± 14.4 22.8 ± 16.4




*F/U window \pm 28 days.

Binary Restenosis at 8 Months*



IVUS In-stent Measures at 8 Months*

XIENCE V (107 lesions) TAXUS (42 lesions)




*F/U window \pm 28 days.


IVUS Incomplete Apposition (Paired lesion serial analysis)

	XIENCE V 90 lesions	TAXUS 43 lesions	P value
Post procedure	34.4%	25.6%	0.33
8 months	25.6%	16.3%	0.27
Resolved	8.9%	9.3%	1.0
Persisting	24.4%	14.0%	0.18
Late acquired	1.1%	2.3%	0.54

IVUS performed in only 1 pt with stent thrombosis, showing no incomplete apposition either post procedure or at FU




TVF Through 284 Days




Spirit III

MACE Through 284 Days





TVF Components Through 270 Days*



*F/U window ± 14 days.


Ischemia-driven TLR Through 284 Days





All Revascularization Through 270 Days*

XIENCE V (658 pts) TAXUS (322 pts)



Conclusions I

- In the large, multicenter, randomized SPIRIT III trial, the everolimus-eluting XIENCE V stent compared to the paclitaxel-eluting TAXUS stent:
 - Was both non-inferior and superior in reducing insegment late loss, the primary endpoint of the trial
 - Significantly reduced in-stent late loss at 8 months
 - Reduced angiographic FU diameter stenosis with a strong trend toward lower binary restenosis
 - Resulted in a significant reduction in in-stent volume obstruction without excess late acquired malapposition



Conclusions II

- In the large, multicenter, randomized SPIRIT III trial, the everolimus-eluting XIENCE V stent compared to the paclitaxel-eluting TAXUS stent:
 - Demonstrated non-inferior rates of TVF at 9 months, with a significant 44% reduction in MACE
 - Showed a strong trend toward reduced ischemia-driven TLR, with a significant reduction in any TLR
 - Had similar rates of death, MI and stent thrombosis
- The primary and major secondary endpoints of the SPIRIT III trial were met

